⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of TrueBlue Clinical Research and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
TrueBlue Clinical Research (TBCR) is a privately owned and operated multi-specialty clinical research site based in Tampa, Florida. The company specializes in conducting Phase Ib through Phase IV clinical trials across a wide range of therapeutic areas, leveraging a large, diverse patient database and a highly trained staff of medical professionals.
Originally founded in 2006 as MOORE Clinical Research, the company rebranded to TrueBlue Clinical Research following its acquisition by PHDermatology in 2022. TBCR is recognized for its strong patient recruitment and retention capabilities, maintaining a significant presence in the Tampa Bay area with advanced site capabilities and digital infrastructure to support decentralized and traditional clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2006
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Site/CRO)
Modalities:Small molecule, Vaccines
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:PHDermatology
Acquired By:PHDermatology (2022-01-01)
Key Partnerships:PHDermatology (Parent), Various Pharmaceutical Sponsors and CROs
COMPETITION
Position:Niche Player
Competitors:Other independent clinical research sites in the Florida region
LEADERSHIP
Key Executives:
Jeffrey Smyth - President | Executive Director
Joseph Cardenas - Vice President | Business Development Director
Scientific Founders:H. Joseph Cardenas
LINKS
Website:tbcrtampa.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TrueBlue Clinical Research. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.